Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.

Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...

The Global Pancreatic Cancer Industry, projecting a valuation of approximately US$ 2,125.57 Million by the end of 2023. The ...

OLD National Bancorp IN lessened its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.0% during the 3rd ...

Blue Trust Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 46.3% during the third quarter, ...